Analysts expect AC Immune SA (NASDAQ:ACIU) to post earnings of ($0.30) per share for the current quarter, Zacks reports. Two analysts have issued estimates for AC Immune’s earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.33). AC Immune posted earnings of ($0.28) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 7.1%. The company is expected to announce its next earnings report on Friday, November 12th.
On average, analysts expect that AC Immune will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($1.20) to $0.11. For the next year, analysts forecast that the business will post earnings of ($0.25) per share, with EPS estimates ranging from ($1.07) to $0.22. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for AC Immune.
AC Immune (NASDAQ:ACIU) last posted its earnings results on Tuesday, August 3rd. The company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.02). AC Immune had a negative net margin of 405.01% and a negative return on equity of 35.48%.
Shares of ACIU traded down $0.03 on Monday, reaching $6.33. 2,298 shares of the company’s stock traded hands, compared to its average volume of 1,117,631. The stock has a market cap of $459.89 million, a PE ratio of -5.68 and a beta of 0.79. The stock’s 50 day simple moving average is $6.84 and its two-hundred day simple moving average is $7.02. AC Immune has a 52-week low of $4.42 and a 52-week high of $12.61.
A number of large investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new stake in shares of AC Immune in the 2nd quarter valued at about $563,000. Morgan Stanley boosted its position in shares of AC Immune by 223.6% in the 2nd quarter. Morgan Stanley now owns 267,935 shares of the company’s stock worth $2,124,000 after purchasing an additional 185,128 shares in the last quarter. Ikarian Capital LLC boosted its position in shares of AC Immune by 63.8% in the 2nd quarter. Ikarian Capital LLC now owns 196,208 shares of the company’s stock worth $1,556,000 after purchasing an additional 76,405 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of AC Immune by 4.4% in the 2nd quarter. Wells Fargo & Company MN now owns 335,104 shares of the company’s stock worth $2,658,000 after purchasing an additional 14,175 shares in the last quarter. Finally, Walleye Trading LLC bought a new position in AC Immune in the 2nd quarter valued at approximately $154,000. 25.04% of the stock is owned by institutional investors.
AC Immune Company Profile
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
Read More: S&P/ASX 200 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.